Mid Cap
Drug Manufacturers - Specialty & Generic
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Dr. Reddy's Laboratories
RDY
$9.82B
| $9.82B | $11.79 | 0.08% |
|
2
Alkermes
ALKS
$8.82B
| $8.82B | $52.89 | 0.15% |
|
3
Liquidia Corp
LQDA
$7.67B
| $7.67B | $86.22 | 3.16% |
|
4
Lantheus
LNTH
$6.82B
| $6.82B | $104.82 | 1.05% |
|
5
Hims & Hers Health
HIMS
$6.5B
| $6.5B | $28.09 | 14.2% |
|
6
Amneal Pharmaceuticals
AMRX
$5.72B
| $5.72B | $17.92 | 0.28% |
|
7
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $4.83B | $62.84 | 0.33% |
|
8
Indivior Pharmaceuticals
INDV
$4.79B
| $4.79B | $40.52 | 0.02% |
|
9
Regencell Bioscience
RGC
$2.83B
| $2.83B | $5.72 | 1.78% |
|
10
Supernus Pharmaceuticals
SUPN
$2.68B
| $2.68B | $46.20 | 2.1% |
|
11
BioCryst Pharmaceuticals
BCRX
$2.37B
| $2.37B | $9.34 | 0.43% |
|
12
Prestige Consumer Healthcare
PBH
$2.35B
| $2.35B | $49.66 | 1.47% |
|
13
Amylyx Pharmaceuticals
AMLX
$2.05B
| $2.05B | $18.41 | 4.66% |
|
Mid Cap Drug Manufacturers - Specialty & Generic Stocks at a Glance
Specialty and generic drug manufacturers develop branded niche therapies, off-patent generics, and animal-health and cannabis products. Generics compete on price and manufacturing scale, while specialty brands carry pharma-like margins on smaller markets.
There are 13 mid cap Drug Manufacturers - Specialty & Generic stocks — companies in the Drug Manufacturers - Specialty & Generic industry with a market cap between $2B and $10B — worth a combined $67.3B.
The largest by market cap are Dr. Reddy's Laboratories (RDY) at $9.82B, Alkermes (ALKS) at $8.82B and Liquidia Corp (LQDA) at $7.67B.
Among institutional investors, Amneal Pharmaceuticals (AMRX) drew the most net new fund positions in Q1 2026: 79 funds opened new positions, taking total fund holders up 38 (14%) quarter-over-quarter.
- Combined market cap: $67.3B across 13 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Dr. Reddy's Laboratories (RDY), $9.82B market cap.
- Most net new fund positions in Q1 2026: Amneal Pharmaceuticals (AMRX), +38 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.